Glenmark Pharmaceuticals receives Establishment Inspection Report (EIS) from U.S. FDA for its Goa facility with VAI classification

September 23, 2026 To, To, National Stock Exchange of India Limited, BSE Limited, “Exchange Plaza”, Corporate Relationship Department, 5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring, Bandra- Kurla Complex, Bandra (East), P.J. Towers, Dalal Street, Mumbai – 400 051 Mumbai – 400 001 Scrip Name: GLENMARK Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 57/26-27 Our Reference No. 57/26-27 Dear Sir/ Madam, Sub: Glenmark Pharmaceuticals receives Establishment Inspection Report (EIR) from U.S. FDA for its Goa facility with VAI classification Glenmark Pharmaceuticals Ltd (Glenmark), a research-led, global pharmaceutical company today announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) for its formulations manufacturing facility in Goa, India with a Voluntary Action Indicated (VAI) status. Kindly find attached media release which is self- explanatory. Request you to take the same on record. Thanking you. For Glenmark Pharmaceuticals Limited Rashmi Khandelwal Company Secretary & Compliance Officer ACS – 28839 Encl: As above Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com Glenmark Pharmaceuticals receives Establishment Inspection Report (EIR) from U.S. FDA for its Goa facility with VAI classification Mumbai, September 23, 2026: Glenmark Pharmaceuticals Ltd (Glenmark), a research-led, global pharmaceutical company today announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) for its formulations manufacturing facility in Goa, India with a Voluntary Action Indicated (VAI) status. The inspection was conducted at the Company’s manufacturing facility from June 22, 2026 to June 30, 2026. About Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research‐led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com For more information, please contact: Akhila Natarajan | mediarelations@glenmarkpharma.com | +91 22 4018 9999 Adfactors PR | glenmark.ihcp@adfactorspr.com |+91 95356 35461